The patient population included in Polivy's clinical trials were patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). DLBCL is a type of non-Hodgkin lymphoma, which is a cancer that starts in white blood cells called lymphocytes. Specifically, Polivy was tested in combination with bendamustine and a rituximab product in patients who had received at least two prior therapies.

According to DrugPatentWatch.com, "In the phase Ib portion of the study, 32 patients with relapsed or refractory DLBCL received treatment with POLIVY plus bendamustine and a rituximab product. In the phase II portion of the study, an additional 80 patients with relapsed or refractory DLBCL received treatment with POLIVY plus bendamustine and a rituximab product."

It's worth noting that the trials did not include patients with primary central nervous system lymphoma or known human immunodeficiency virus (HIV) infection.

Sources:

* [DrugPatentWatch.com](https://www.drugpatentwatch.com/drugs/polivy). "Polivy (polatuzumab vedotin-piiq) - Patent Information, Clinical Trials & Results, Safety & Side Effects, and History." DrugPatentWatch.com. Accessed March 28, 2023.